Pipeline

As of May 10, 2024

Ethical Pharmaceuticals

Stage	Name	Type	Efficacy Classification	Notes
Approved (Japan) Filed (South Korea, Taiwan, Thailand)	ME3208 (Belumosudil)	Oral	Chronic Graft Versus Host Disease	Product name (Japan): REZUROCK Tablets Partnership: Romeck Pharma, LLC
Filed (Overseas)^* Phase Ⅰ (Japan)	DMB-3115	Injection	Plaque psoriasis/Psoriatic arthritis/Crohn's disease/Ulcerative colitis (Biosimilar)	Co-development: Dong-A ST Co., Ltd. (South Korea) Out-license: Intas Pharmaceuticals Ltd. (India)
Phase Ⅲ (Japan, Overseas)	HBI-8000 (Tucidinostat)	Oral	Unresectable or metastatic melanoma	Co-development: HUYABIO International, LLC (USA) Multi-Regional Clinical Trials
Phase Ⅲ (Japan, Overseas)	OP0595 (Nacubactam)	Injection	β-lactamase inhibitor	Discovered in-house Multi-Regional Clinical Trials
Phase Ⅱ (Overseas)	ME3183	Oral	Psoriasis/Selective PDE4 inhibitor	Discovered in-house
Phase Ⅰb / Ⅱ (Japan)	HBI-8000 (Tucidinostat)	Oral	Relapsed or refractory B-cell non-Hodgkin's lymphoma	In-license: HUYABIO International, LLC (USA) Multi-Regional Clinical Trials

Human Vaccines

Stage	Name	Target Disease	Notes
Approved (Japan)	KD-370	Pentavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, and Haemophilus influenzae type b	Product name: Quintovac Aqueous Suspension Injection
Approved (Japan)	ARCT-154	Self-amplifying mRNA vaccine against COVID-19	Product name: Kostaive Partnership: CSL Seqirus (Australia)
Phase Ⅲ (Japan)	ARCT-2301	Self-amplifying mRNA vaccine against COVID-19 (Bivalent: Original strain and Omicron strain)	Partnership: CSL Seqirus (Australia)
Phase Ⅲ (Japan)	KD-414	Inactivated vaccine against COVID-19 (Adults^*)	Multi-Regional Clinical Trials * 18-40 years old
Phase Ⅲ (Japan)	KD-414	Inactivated vaccine against COVID-19 (Pediatric^*)	* 6 months - 11 years old
Phase Ⅲ (Japan)	KD-414	Inactivated vaccine against COVID-19 (Pediatric^*, Omicron strain)	* 6 months - 12 years old
Phase Ⅱ (Japan)	KD2-396	Hexavalent vaccine against diphtheria, tetanus, pertussis, poliovirus, Haemophilus influenzae type b, and Hepatitis B virus
Phase Ⅰ (Overseas)	KD-382	Live attenuated tetravalent vaccine against dengue fever

Veterinary Drugs

Stage	Name	Efficacy Classification	Notes
Approved (Japan)	ME4137	Injectable antibacterial drug for cattle	Product name: FORCYL
Filed (Japan)	ME4137	Injectable antibacterial drug for swine
Filed (Japan)	KD-412	Vaccine for cattle	Discovered in-house
Filed (Japan)	MD-22-3002	Anti-inflammatory drug for cattle, swine and horse
Under development	ME4305	Antibacterial drug for cattle	Discovered in-house
Under development	MD-22-1001-1	Injectable antibacterial drug for cattle
Under development	ME4406	Feed Additive	Discovered in-house

Have a question?
Contact us here.

CONTACT US

Meiji Seika Pharma Co., Ltd.

Based in Japan, we are a leading developer and manufacturer of antibacterial drugs, vaccines and biotech solutions, with a history of over 75 years.

Location

Headquarters: 2-4-16 Kyobashi, Chuo-ku, Tokyo104-8002 Japan